CN106573038A - 螺杆菌治疗剂 - Google Patents

螺杆菌治疗剂 Download PDF

Info

Publication number
CN106573038A
CN106573038A CN201580035276.6A CN201580035276A CN106573038A CN 106573038 A CN106573038 A CN 106573038A CN 201580035276 A CN201580035276 A CN 201580035276A CN 106573038 A CN106573038 A CN 106573038A
Authority
CN
China
Prior art keywords
gly
ile
lys
asn
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580035276.6A
Other languages
English (en)
Chinese (zh)
Inventor
菲利普·萨顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Murdoch Childrens Research Institute
Original Assignee
Murdoch Childrens Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902493A external-priority patent/AU2014902493A0/en
Application filed by Murdoch Childrens Research Institute filed Critical Murdoch Childrens Research Institute
Priority to CN202110962088.5A priority Critical patent/CN113694191A/zh
Publication of CN106573038A publication Critical patent/CN106573038A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580035276.6A 2014-06-30 2015-06-30 螺杆菌治疗剂 Pending CN106573038A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110962088.5A CN113694191A (zh) 2014-06-30 2015-06-30 螺杆菌治疗剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014902493A AU2014902493A0 (en) 2014-06-30 Helicobacter therapeutic
AU2014902493 2014-06-30
PCT/AU2015/000380 WO2016000022A1 (en) 2014-06-30 2015-06-30 Helicobacter therapeutic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110962088.5A Division CN113694191A (zh) 2014-06-30 2015-06-30 螺杆菌治疗剂

Publications (1)

Publication Number Publication Date
CN106573038A true CN106573038A (zh) 2017-04-19

Family

ID=55018143

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580035276.6A Pending CN106573038A (zh) 2014-06-30 2015-06-30 螺杆菌治疗剂
CN202110962088.5A Pending CN113694191A (zh) 2014-06-30 2015-06-30 螺杆菌治疗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110962088.5A Pending CN113694191A (zh) 2014-06-30 2015-06-30 螺杆菌治疗剂

Country Status (9)

Country Link
US (3) US20170165347A1 (enExample)
EP (1) EP3160492A4 (enExample)
JP (1) JP6634444B2 (enExample)
KR (1) KR102481455B1 (enExample)
CN (2) CN106573038A (enExample)
AU (1) AU2015283805B2 (enExample)
BR (1) BR112016030728A2 (enExample)
RU (1) RU2017100658A (enExample)
WO (1) WO2016000022A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108531468A (zh) * 2018-02-24 2018-09-14 广东工业大学 编码重组幽门螺杆菌丝氨酸蛋白酶的基因、卵黄抗体与应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101885460B1 (ko) 2017-02-07 2018-08-03 두산중공업 주식회사 가스터빈용 프리 스월러 장치
KR102500799B1 (ko) 2018-03-09 2023-02-20 삼성디스플레이 주식회사 트랜지스터 기판 및 이를 구비하는 표시 장치
RU2746590C1 (ru) * 2020-10-12 2021-04-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Вятский государственный университет" Способ эрадикации бактерий Helicobacter pylori при экспериментальном хеликобактериозе у конвенциональных белых мышей и средство для его осуществления

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049314A2 (en) * 1997-04-25 1998-11-05 Genelabs Technologies, Inc. ANTIGENIC COMPOSITION AND METHOD OF DETECTION FOR $i(HELICOBACTER PYLORI)
WO2001032014A2 (en) * 1999-11-01 2001-05-10 Oravax, Inc. Use of salmonella vectors for vaccination against hellicobacter infection
CN1331748A (zh) * 1998-10-30 2002-01-16 默多克研究所 重组方法及其所用试剂
CN101443353A (zh) * 2006-03-15 2009-05-27 Csir公司 谷氨酰胺合成酶活性的调节

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
ATE475668T1 (de) 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
AU3210997A (en) 1996-05-24 1997-12-09 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
GB9808720D0 (en) * 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US20030180330A1 (en) * 2000-04-27 2003-09-25 Meyer Thomas F Method for identifying helicobacter antigens
US7015033B1 (en) * 2000-05-25 2006-03-21 Aventis Pasteur Limited Co-expression of recombination proteins
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
JP2007524366A (ja) * 2003-04-22 2007-08-30 インターツェル・アクチェンゲゼルシャフト ピロリ菌抗原
US7868139B2 (en) * 2006-01-24 2011-01-11 Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
US20110250221A1 (en) * 2007-08-24 2011-10-13 University Of Wollongong Group A Streptococcus Pharmaceutical Compositions and Methods Thereof
WO2010068413A1 (en) * 2008-11-25 2010-06-17 Emergent Product Development Gaithersburg Inc. Chlamydia vaccine comprising htra polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049314A2 (en) * 1997-04-25 1998-11-05 Genelabs Technologies, Inc. ANTIGENIC COMPOSITION AND METHOD OF DETECTION FOR $i(HELICOBACTER PYLORI)
CN1331748A (zh) * 1998-10-30 2002-01-16 默多克研究所 重组方法及其所用试剂
WO2001032014A2 (en) * 1999-11-01 2001-05-10 Oravax, Inc. Use of salmonella vectors for vaccination against hellicobacter infection
CN101443353A (zh) * 2006-03-15 2009-05-27 Csir公司 谷氨酰胺合成酶活性的调节

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENJAMIN HOY等: "Helicobacter pylori HtrA is a new secreted virulence factor that cleaves E-cadherin to disrupt intercellular adhesion", 《EMBO REPORTS》 *
LOWER,M.等: "GenBank: DAA34967.1，TPA_exp: secreted serine protease HtrA [Helicobacter pylori 26695]", 《GENBANK》 *
金雷等: "HtrA1丝氨酸蛋白酶研究进展", 《肝胆胰外科杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108531468A (zh) * 2018-02-24 2018-09-14 广东工业大学 编码重组幽门螺杆菌丝氨酸蛋白酶的基因、卵黄抗体与应用
CN108531468B (zh) * 2018-02-24 2020-07-17 广东工业大学 编码重组幽门螺杆菌丝氨酸蛋白酶的基因、卵黄抗体与应用

Also Published As

Publication number Publication date
US20170165347A1 (en) 2017-06-15
US20220193216A1 (en) 2022-06-23
KR20170016989A (ko) 2017-02-14
EP3160492A4 (en) 2018-01-03
AU2015283805A1 (en) 2017-01-05
JP2017521490A (ja) 2017-08-03
JP6634444B2 (ja) 2020-01-22
EP3160492A1 (en) 2017-05-03
RU2017100658A3 (enExample) 2019-02-19
CN113694191A (zh) 2021-11-26
RU2017100658A (ru) 2018-07-30
WO2016000022A1 (en) 2016-01-07
KR102481455B1 (ko) 2022-12-26
BR112016030728A2 (pt) 2018-02-20
US20200108135A1 (en) 2020-04-09
AU2015283805B2 (en) 2021-02-25
US11819546B2 (en) 2023-11-21

Similar Documents

Publication Publication Date Title
US11819546B2 (en) Helicobacter therapeutic
JP6670304B2 (ja) ストレプトコッカス・スイス感染に対するワクチン組成物
TWI681972B (zh) 抗免疫原性醣肽之抗體，包含彼等之組合物及其用途
EP1708749B1 (en) Mucosal vaccine adjuvants containing bacterial flegellins as an active component
CN107073095A (zh) 基于脂多糖缺失的细胞组分的抗鲍氏不动杆菌疫苗
WO2012048553A1 (zh) 大肠杆菌TolC抗原及其抗体与应用
HUE033342T2 (en) Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
Harokopakis et al. Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of coexpressed cholera toxin A2 and B subunits
Liu et al. Therapeutic efficacy of oral immunization with a non-genetically modified Lactococcus lactis-based vaccine CUE-GEM induces local immunity against Helicobacter pylori infection
CN108135992A (zh) 免疫原性融合蛋白
CN108770343A (zh) 用于治疗癌症的使用MICA/Bα3结构域的疫苗接种
JP5661744B2 (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
Gallagher et al. Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis
Liu et al. Nongenetically modified Lactococcus lactis‐adjuvanted vaccination enhanced innate immunity against Helicobacter pylori
JP2017518769A (ja) 免疫低下状態の宿主のためのワクチン
US6838553B1 (en) Peptide repeat immunogens
US11185583B2 (en) Multi-functional mucosal vaccine platform
CN115151559A (zh) 葡萄球菌肽和使用方法
JP7410018B2 (ja) Ａ群レンサ球菌に対する免疫原性ペプチド
WO2011018779A1 (en) Modified helicobacter protein
KR20210010882A (ko) 연쇄구균 독성 쇼크 증후군
EP2004222A2 (en) Vaccine
Eyles et al. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity
WO2009144240A1 (en) Composition and method for the assay and treatment of anthrax
IE20100505A1 (en) Modified helicobacter protein

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170419